We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Synairgen Plc | LSE:SNG | London | Ordinary Share | GB00B0381Z20 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 6.24 | 5.52 | 7.00 | - | 1,385 | 08:09:18 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 0 | -17.65M | -0.0876 | -0.71 | 12.56M |
Date | Subject | Author | Discuss |
---|---|---|---|
11/4/2021 14:17 | You can tell how desperate the shorters are by how frequently they post. Including those that purport to have shares . | hazl | |
11/4/2021 14:12 | https://amp.theguard | tickboo | |
11/4/2021 13:31 | The thing is with the huge worldwide vaccination programme being so successful the countries that can afford our product are now seeing huge drops in the people needing CV 19 treatment We missed the bus we could have done with catching and the last one is due to leave shortly So need news before this last bus departs imho | judijudi | |
11/4/2021 11:37 | A reminder. 'Shaun Chilton, Clinigen Chief Executive Officer, added: "We are working with a number of companies who have products being tested against COVID-19 and are very pleased to be working with Synairgen to make this highly promising COVID-19 treatment available internationally. The early study results demonstrate that SNG001 may have a vital role in helping hospitalised patients recover more quickly from the disease." | hazl | |
10/4/2021 19:49 | Stay happy (and polite) JJ! | nobbygnome | |
10/4/2021 18:44 | I also said it bodes well for SNG001 and he was kind enough to reply -Yes, in most patients the auto-Abs to type I IFNs neutralize the 13 alphas and/or omega but not beta ... | tickboo |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions